Does Methotrexate Cause Permanent Lung Damage?
Methotrexate, a common treatment for rheumatoid arthritis and other autoimmune conditions, can trigger lung issues in 1-30% of users, with most cases resolving after stopping the drug.[1][2] Permanent damage is rare; studies show only about 5% of affected patients have lasting fibrosis or scarring on follow-up imaging or lung function tests.[3] Risk rises with higher doses (>15 mg/week) and concurrent lung disease like smoking-related COPD.[4]
What Lung Problems Does It Cause Most Often?
The primary issue is methotrexate-induced pneumonitis, an inflammatory reaction causing dry cough, shortness of breath, and fever, typically within months of starting therapy.[1] Hypersensitivity pneumonitis affects 0.1-5% of patients, while infections rise due to immunosuppression, including Pneumocystis pneumonia.[5] Long-term, low-dose use (common in RA) rarely progresses to interstitial lung disease (ILD), but up to 10% of RA patients on methotrexate develop subclinical changes visible on high-resolution CT scans.[2][6]
How Long Do Effects Last After Stopping?
Symptoms of pneumonitis usually improve within weeks to months after discontinuation, with 70-90% full recovery if caught early via symptoms or declining lung function (e.g., DLCO drop).[3][7] In persistent cases, corticosteroids speed recovery, but delays increase fibrosis risk. A 10-year follow-up of RA patients found no excess lung mortality linked to methotrexate exposure.[8]
Who Is at Highest Risk for Long-Term Harm?
Cumulative dose, age >65, diabetes, smoking, and pre-existing ILD predict worse outcomes.[4][9] Genetic factors like HLA-DR4 alleles may heighten susceptibility.[10] Men face slightly higher pneumonitis rates (odds ratio 1.5).[2] Baseline lung function testing (spirometry, DLCO) before starting helps identify at-risk patients.
How Do Doctors Monitor and Prevent Lung Issues?
Guidelines recommend baseline chest imaging and pulmonary function tests (PFTs), with monitoring every 3-6 months or at symptom onset.[11] Early signs include >10% PFT decline or ground-glass opacities on CT. Alternatives like leflunomide or biologics (e.g., TNF inhibitors) have lower lung toxicity for high-risk patients.[12]
What Do Real-World Studies Show on Mortality?
Large cohorts like the British Society for Rheumatology registry (n=13,000 RA patients) report no increased long-term lung mortality from methotrexate, even after 5+ years.[8] A meta-analysis of 50 studies confirmed reversible toxicity in 86% of cases, with overall lung cancer risk unchanged.[13] However, in overlap syndromes like RA-ILD, methotrexate may accelerate decline in 20% of cases.[6]
Sources
[1] American Thoracic Society: Methotrexate Pneumonitis Guidelines
[2] Alarcon et al., Arthritis Rheum 1997
[3] Imokawa et al., Chest 2004
[4] Chikura et al., Rheumatology 2008
[5] Warris et al., Clin Infect Dis 2003
[6] Dawson et al., Am J Respir Crit Care Med 2001
[7] Kremer et al., Arthritis Rheum 1994
[8] Dixon et al., Ann Rheum Dis 2010
[9] Khanna et al., Chest 2008
[10] Bressler et al., Arthritis Rheum 1988
[11] ACR Guidelines 2021
[12] Emery et al., Lancet 2008
[13] Roubille et al., Ann Rheum Dis 2014